Dexcom AI Stock Analysis
Want to see DXCM full AI Analyst Report?
Dexcom (DXCM) AI Stock Analysis
Dexcom
(NASDAQ:DXCM)
Score is driven primarily by strong financial performance and a bullish earnings call (raised guidance and margin expansion). Offsetting these positives, technical indicators are weak with the stock trading below key moving averages and negative MACD, and valuation remains premium with a ~30.9 P/E and no dividend yield provided.
Dexcom Key Performance Indicators (KPIs)
Revenue by SegmentShows how revenue is distributed across different business segments, highlighting which areas are driving growth and which may need strategic attention.
DexCom's Sensor and Other segment shows strong growth momentum, with recent quarters reflecting significant revenue increases. This aligns with the earnings call, which highlights robust revenue growth and strategic expansions, particularly in type 2 diabetes CGM coverage. However, the Hardware segment is experiencing a decline, possibly due to quality and deployment issues with the G7 sensor. Despite these challenges, DexCom's strategic innovations like the Smart Basal and successful product launches such as Stelo are driving positive sentiment and long-term growth prospects.
Dexcom (DXCM) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $30.44B
- Dividend Yield
- ―
- Average Volume (3M)
- 4.23M
- Price to Earnings (P/E)
- 31.6
- Beta (1Y)
- 1.16
- Revenue Growth
- 13.03%
- EPS Growth
- 40.88%
- Country
- US
- Employees
- 11,050
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Dexcom Business Overview & Revenue Model
Company Description
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individua...
How the Company Makes Money
Dexcom primarily makes money by selling CGM products and related supplies on a recurring-use model. Its core revenue stream is the sale of disposable CGM sensors that must be replaced regularly, creating repeat, ongoing demand from existing users. Ad...
Dexcom Earnings Call Summary
The call was strongly positive. Dexcom reported 11% worldwide revenue growth, 14% U.S. growth, continued market-share gains, near-record new patient starts, significant gross-margin and EBITDA-margin expansion, strong cash generation, raised operating and EBITDA margin guidance, and substantial progress in clinical evidence, product launches, manufacturing, and future access expansion. The main challenges were slower international growth, near-term Ireland ramp effects, incremental foreign-exchange headwinds, higher operating expenses, and the loss of preferred access under a PBM representing less than 4% of U.S. revenue. Highlights significantly outweighed the lowlights.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Dexcom updated full year revenue guidance to be in the range of $5.20 billion to $5.25 billion, representing growth of 12% to 13% for the year, with midpoint fourth quarter growth of 10%; it maintained full year non-GAAP gross profit margin guidance at approximately 64% and increased non-GAAP operating profit margin guidance to approximately 24% and adjusted EBITDA margin guidance to approximately 32%. Dexcom expects to convert nearly 50% of its U.S. customer base to G7 15 Day by year-end, expects CMS to announce a type 2 non-insulin coverage decision this year with coverage taking effect middle of next year, and is still targeting GA for either launching at the end of next year or early '28, depending on regulatory review time lines.
Dexcom Financial Statement Overview
Summary
Strong overall fundamentals: accelerating TTM revenue to $5.10B, solid profitability (~63% gross margin, ~19% net margin), and improved leverage (debt-to-equity ~0.53). The main offset is weakening cash conversion and momentum, with free cash flow down meaningfully in the latest TTM and operating cash flow below net income.
Income Statement
90Very PositiveBalance Sheet
82Very PositiveCash Flow
74Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.10B | 4.66B | 4.03B | 3.62B | 2.91B | 2.45B |
| Gross Profit | 3.24B | 2.80B | 2.44B | 2.29B | 1.88B | 1.68B |
| EBITDA | 1.55B | 1.36B | 945.70M | 916.70M | 565.30M | 377.60M |
| Net Income | 991.00M | 836.30M | 576.20M | 541.50M | 341.20M | 216.90M |
Balance Sheet | ||||||
| Total Assets | 6.24B | 6.34B | 6.48B | 6.26B | 5.39B | 4.93B |
| Cash, Cash Equivalents and Short-Term Investments | 1.82B | 2.00B | 2.58B | 2.72B | 2.46B | 2.73B |
| Total Debt | 1.39B | 1.39B | 2.59B | 2.59B | 2.15B | 2.16B |
| Total Liabilities | 3.70B | 3.59B | 4.38B | 4.20B | 3.26B | 2.89B |
| Stockholders Equity | 2.54B | 2.75B | 2.10B | 2.07B | 2.13B | 2.04B |
Cash Flow | ||||||
| Free Cash Flow | 1.10B | 1.08B | 630.70M | 511.90M | 304.70M | 53.30M |
| Operating Cash Flow | 1.41B | 1.44B | 989.50M | 748.50M | 669.50M | 442.50M |
| Investing Cash Flow | 261.20M | 536.00M | -207.50M | -507.20M | -521.50M | -216.10M |
| Financing Cash Flow | -2.55B | -1.69B | -734.80M | -318.60M | -552.50M | 10.40M |
Dexcom Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DXCM, the sentiment is Neutral. The current price of 81.61 is above the 20-day moving average (MA) of 81.40, below the 50-day MA of 84.17, and above the 200-day MA of 75.12, indicating a neutral trend. The MACD of -0.66 indicates Negative momentum. The RSI at 47.90 is Neutral, neither overbought nor oversold. The STOCH value of 28.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DXCM.
Dexcom Risk Analysis
Dexcom disclosed 75 risk factors in its most recent earnings report. Dexcom reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksDexcom Peers Comparison
Overall Rating
MDT81Outperform
PODD73Outperform
DXCM73Outperform
ABT67Neutral
TNDM60Neutral
SENS50Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 81Outperform | $131.60B | 25.27 | 10.60% | 2.78% | 9.77% | 12.28% | |
| 73Outperform | $10.08B | 23.79 | 29.48% | ― | 26.46% | 75.56% | |
| 73Outperform | $30.44B | 31.61 | 36.50% | ― | 13.03% | 40.88% | |
| 67Neutral | $186.10B | 39.96 | 9.11% | 2.35% | 10.00% | -66.06% | |
| 60Neutral | $1.29B | -26.22 | -35.61% | ― | 6.73% | 76.54% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 50Neutral | $597.11M | -4.72 | -186.15% | ― | 104.83% | -37.15% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DXCM | Dexcom | 81.61 | 21.88 | 36.63% | |
| ABT | Abbott Laboratories | 107.45 | -15.64 | -12.71% | |
| PODD | Insulet | 145.29 | -201.07 | -58.05% | |
| MDT | Medtronic | 102.88 | 5.76 | 5.93% | |
| TNDM | Tandem Diabetes Care | 18.48 | -0.26 | -1.39% | |
| SENS | Senseonics Holdings Inc. | 10.90 | 5.26 | 93.26% |
Dexcom Corporate Events
Dexcom Lifts 2026 Outlook After Strong Q3 Results
PositiveOn October 29, 2026, Dexcom reported third-quarter 2026 results with worldwide revenue up 11% year-over-year to $1.344 billion, improved GAAP and non-GAAP margins, and GAAP net income of $275.1 million, supported by $1.82 billion in cash, cash equiva...
Dexcom Elevates Jereme Sylvain to COO and CFO
PositiveOn September 10, 2026, Dexcom’s board appointed Executive Vice President and Chief Financial Officer Jereme Sylvain to the expanded role of Executive Vice President, Chief Operating Officer and Chief Financial Officer, effective September 14, 2026. H...
Dexcom appoints Glenn Boehnlein to board of directors
PositiveOn September 10, 2026, Dexcom’s Board of Directors expanded its size to thirteen members and appointed veteran medical technology finance executive Glenn S. Boehnlein as an independent director, effective immediately, with his term running until the...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 30, 2026
